
Diabetes
| Acute and Chronic Complications
Diabetes
Acute and Chronic Complications

Effects of Empagliflozin on Glucose Metabolism and Body Fat Composition in Patients with Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
book_2
Source:
ADA 2020 - Poster session
calendar_today
Published on Medfyle:
July 2020
headphones
3
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Beneficial effects of SGLT2 inhibitors on glucose metabolism, body adiposity, and liver fat content are well established in diabetes.
- As the mode of action of SGLT2 inhibitors partly depends on elevated blood glucose, we now investigate if these effects also occur in prediabetes.
- Treatment with empagliflozin for 8 weeks had no major effects on glucose metabolism.
- Though, SGLT2 inhibition reduced body adiposity and liver fat content, presumably by shifting energy metabolism towards lipid oxidation.
- Empagliflozin might represent a treatment option for obesity and hepatic steatosis in prediabetes, independent of drug effects on blood glucose.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Julia Hummel MSc, PhD
Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, University of Tübingen
German Center for Diabetes Research, Neuherberg, Germany